Company News_Frontera Therapeutics, Inc.

: Frontera Therapeutics’ FT-003 Achieves Regenerative Medicine Advanced Therapy Designation from the U.S. FDA for Neovascular Age-Related Macular Degeneration

Shanghai/Boston, July 29, 2026 — Frontera Therapeutics, a clinical-stage biotechnology company focused on innovative AAV gene therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its core product FT-003 for the treatment of neovascular age-related macular degeneration (nAMD). FT-003 is the first gene therapy product in China to receive RMAT designation for the (nAMD) indication.
2026-07-29

: Frontera Therapeutics Presents Positive Top-Line Phase II Data for FT-002 and FT-003 at ARVO 2026

FT-002 Demonstrates Sustained Vision Improvements in Pediatric XLRP Participants; FT-003 Shows Durable Visual Gains with Substantially Reduced Injection Burden in nAMD
2026-05-11

: Frontera Therapeutics Won 2026 Forbes China Industry Development Leader Award

Frontera Therapeutics Won 2026 Forbes China Industry Development Leader Award
2026-03-20

: 【Conference Announcement】Frontera Therapeutics to Present Innovative Achievements at ARVO 2026

Frontera Therapeutics will present multiple latest clinical research achievements at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), a globally authoritative academic event.
2026-03-06

: Highlights of the 5th Next Generation Gene Therapy Vectors Summit: Frontera Therapeutics Achieves Breakthroughs in Payload Innovation

Dr. Zhong-Dong Shi, Vice President of R&D at Frontera Therapeutics, was invited as a keynote speaker to deliver "Engineering Payload to Increase Expression Durability & Lower Dose"
2025-08-13

: FT-017 Gains FDA and CDE Approval, Pioneering Gene Therapy for Hypertrophic Cardiomyopathy

April 27, 2025 — Frontera Therapeutics announced today that its recombinant adeno-associated virus (rAAV) gene therapy, FT-017, has received clinical trial clearance from both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA).
2025-04-28

Company News